menu

NEWS

Wastewater Testing Labs Can Automate Sample Processing for High Throughput With All-In-One Kit

New purification system launched by Promega includes Ceres Nanosciences’ Nanotrap® particles for virus concentration MADISON, Wis.–(BUSINESS WIRE)–Wastewater testing labs can now scale up their infectious disease surveillance using two reliable technologies in a single kit. The new system released by Promega Corporation pairs the company’s Maxwell® HT chemistry with Ceres Nanosciences’ Nanotrap® particles, an established technology for capturing and concentrating low-abundance analytes such as viral particles. Together, these technologies empower labs to purify pathogen nucleic acids from wastewater samples in high-throughput workflows. “Ceres has a technology that enables concentration of microbes from wastewater that is unique to the market”Tweet this “Ceres has a...

READ MORE
Ceres Nanosciences Receives $1.4M From NIH RADx Initiative to Add Five Additional Wastewater-Based Epidemiology Centers of Excellence

Manassas, Virginia – December 2, 2022 Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, is announcing today that it is expanding the network of wastewater-based epidemiology centers of excellence that was established with support from the National Institutes of Health (NIH) RADx® initiative. With a new $1.4 million award from the NIH, Ceres will identify and establish five additional centers of excellence to join the existing network of 16 sites comprising public health labs, non-profit labs, university labs, and commercial testing labs in 14 states. Ceres also will support the verification of...

READ MORE
Genetika+ Snags CE Mark for Major Depressive Disorder Drug-Matching Test

October 19, 2022 | Staff Reporter – genomeweb NEW YORK – Genetika+ has obtained CE-IVD marking for its first drug-matching test focused on major depressive disorder (MDD), the precision medicine startup said Wednesday. The Israeli company’s product, a blood test dubbed NeuroKaire, is ordered by a physician. It predicts a patient’s likelihood of responding to various antidepressants by combining patient-reported information about symptoms with pharmacogenetics testing and functional testing based on the patient’s blood sample.  The company’s CE mark follows results from a multi-site study, in which NeuroKaire successfully predicted drug response for patients with MDD. “This CE-IVD mark is an...

READ MORE
Genetika+ Combines PGx, ‘Brain-in-a-Dish’ Model to Personalize Depression Meds

October 11, 2022 | Jessica Kim Cohen – genomeweb NEW YORK – Genetika+ is combining information on patients’ symptoms, pharmacogenetics, and aso-called “brain-in-a-dish” functional testing model in the hopes of improving personalized drugprescribing for psychiatric conditions, with an initial focus on depression.  The Israeli company plans to launch its first drug-matching testing service for major depressivedisorder, dubbed NeuroKaire, next year. Genetika+ hopes to promote NeuroKaire as a service doctorscan use to improve patients’ outcomes on antidepressants, reduce treatment-related side effects, andcut down on trial-and-error prescribing. Millions of people across the globe struggle with major depressive disorder, and prevalence hasincreased with...

READ MORE
Streck Announces Series B Investment in Ceres Nanosciences

La Vista, Nebraska – September 14, 2022 Streck announced today a Series B investment in Ceres Nanosciences (Ceres). The funds from this investment will be used to accelerate the development and commercialization of both diagnostic and research use products utilizing Ceres’ Nanotrap® technology platform. “Streck has a deep presence in and knowledge of the diagnostics industry and shares our commitment to building long-term relationships with partners and customers,” said Ceres CEO Ross Dunlap. “We are thrilled to have Streck’s support and guidance in this next, exciting phase of our growth.” This investment builds on the pre-existing partnership between Ceres and Streck,...

READ MORE
KSM Research And Innovation And Genetika+ Partner To Seek AI Solutions For Personalization Of Depression Treatment

Kahn-Sagol-Maccabi (KSM) and Genetika+ form a research partnership to develop and validate AI that personalizes and speeds up an optimal depression treatment TEL AVIV, ISRAEL, August 15, 2022 /EINPresswire.com/ — Kahn-Sagol-Maccabi (KSM), the research and innovation center of Israel’s Maccabi Healthcare Services, and Genetika+, a pioneer in personalized medicine for the brain, are partnering to advance the development of tools to personalize depression treatment using Artificial Intelligence (AI) and advanced analytics. The collaboration between Genetika+ and KSM is focused on conducting large-scale state-of-the-art analysis on extensive data from patients suffering from depression in order to further develop and validate Genetika+’s...

READ MORE
1 2 3 4 9
GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.

MEET THE PEOPLE

For additional information, please contact: greybird@greybirdventures.com

DISCLAIMER